OBJECTIVES: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune inflammatory disorder of the peripheral nervous system. Evidence is limited with the real-world patient population. The aim of the study is to better understand patient demographics, diagnostic journey, healthcare resource utilization (HCRU) and treatment patterns of patients in the Inspire CIDP cohort using primarily medical claims and user-generated contents.

METHODS: A retrospective study using data from the Inspire Integrated Analytical Database, which links Inspire member data with medical and pharmacy claims through HIPAA-compliant tokenization. Inspire members with ≥ 1 diagnosis of CIDP (ICD-10 G61.81) from 01/01/2015 to 11/30/2021 were included. Index date was defined as the date of first claim with a CIDP diagnosis. Baseline patient characteristics and all-cause and CIDP-related HCRU were evaluated. Descriptive statistics were reported.

RESULTS: A total of 438 CIDP patients were identified, with median followup time of 48 months from index date. The median age at diagnosis is 55 and 60% of patients were female. Patients were geographically represented across the US. About 90% of the cohort had ≥100 claims from a median of 28 care sites across 36 providers. The median number of hospitalizations was 2. 37% of patients received OT/PT and 20% have a claim for electromyography or nerve conduction studies prior to their CIDP diagnosis. 32% of patients had a previous diagnosis of unspecified polyneuropathy. Median time from the first diagnostic procedure to index diagnosis was 8.5 months. Top 5 most common topics viewed on Inspire among the cohort include: Skin, Side effect, Muscle, Drug and Nerve.

CONCLUSIONS: CIDP patients in this ongoing retrospective analysis had a median of 4+ years of healthcare visit data since diagnosis. Majority of patients had 100+ claims, which indicate substantial healthcare resource utilization. CIDP patients endure a long diagnostic journey to undergo appropriate treatment.